Roivant Sciences (ROIV) Accumulated Expenses (2021 - 2026)

Roivant Sciences has reported Accumulated Expenses for 6 years, with the latest figure at $205.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 80.08% year-over-year to $205.8 million; the trailing twelve-month figure through Mar 2026 stood at $205.8 million (up 80.08% YoY), and the FY2026 full-year result was $205.8 million, up 80.08% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $205.8 million, up from $118.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $205.8 million in Q1 2026, with the low at $19.9 million in Q2 2023.
• Historically, Accumulated Expenses has averaged $94.1 million across 5 years, with a median of $109.4 million in 2022.
• Annual changes were most pronounced in 2023 — Accumulated Expenses sank 81.78% — and 2024, when it jumped 594.11%.
• Roivant Sciences' Accumulated Expenses stood at $41.9 million in 2022, then jumped by 83.46% to $76.9 million in 2023, then slumped by 48.92% to $39.3 million in 2024, then surged by 200.4% to $118.0 million in 2025, then jumped by 74.44% to $205.8 million in 2026.
• The last three Accumulated Expenses figures came in at $205.8 million (Q1 2026), $118.0 million (Q4 2025), and $108.3 million (Q3 2025), per Business Quant data.